Cargando…

β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a chronic disease characterized by inflammation, steatosis, and liver fibrosis. The liver is particularly affected by alterations in lipid metabolism. Our aim was to evaluate the effect of β-hydroxyphosphocarnitine (β-HPC) on NASH induced in rats....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Quevedo, Janet, Ocampo-Rodríguez, Emmanuel, Alvarez-Ayala, Elizabeth, Rodríguez-López, Anahí, Duarte-Vázquez, Miguel Angel, Rosado, Jorge Luis, Rodríguez-Fragoso, Lourdes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520892/ https://www.ncbi.nlm.nih.gov/pubmed/36175992 http://dx.doi.org/10.1186/s40360-022-00613-2

Ejemplares similares

Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice
por: Wollman, Ayala, et al.
Publicado: (2019)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis
por: Ju, Linling, et al.
Publicado: (2020)

Steatosis and Steatohepatitis: Complex Disorders
por: Bettermann, Kira, et al.
Publicado: (2014)

Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story
por: Cataldi, Mauro, et al.
Publicado: (2021)

Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis
por: Wattacheril, Julia, et al.
Publicado: (2013)

Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress
por: Zhang, Zhiguo, et al.
Publicado: (2016)

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis
por: Mendel, Itzhak, et al.
Publicado: (2016)

The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients
por: Ganjooei, Narges Ashraf, et al.
Publicado: (2021)

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
por: Lee, Kuei-Chuan, et al.
Publicado: (2023)

Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation
por: Li, Zhiqiang, et al.
Publicado: (2021)

Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis
por: Pastori, Daniele, et al.
Publicado: (2015)

P2X7 Receptor in Alcoholic Steatohepatitis and Alcoholic Liver Fibrosis
por: Xia, Guo-Qing, et al.
Publicado: (2022)

EGF-receptor phosphorylation and downstream signaling are activated by genistein during subacute liver damage
por: Ayala-Calvillo, Erick, et al.
Publicado: (2023)

Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
por: Phisalprapa, Pochamana, et al.
Publicado: (2021)

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children
por: Kordy, Kattayoun, et al.
Publicado: (2021)

AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line
por: Yehezkel, Adi S., et al.
Publicado: (2023)

Immuno-Modulator Metallo-Peptide Reduces Inflammatory State in Obese Zucker Fa/Fa Rats
por: Gómez-Solís, Antonieta, et al.
Publicado: (2014)

Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model
por: Xiao, Jia, et al.
Publicado: (2014)

Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis
por: Vulf, Maria, et al.
Publicado: (2021)

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
por: Matsumoto, Masahiko, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
por: Verlinden, Wim, et al.
Publicado: (2020)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy‐Confirmed Mouse Model of Advanced Non‐Alcoholic Steatohepatitis and Fibrosis
por: Kannt, Aimo, et al.
Publicado: (2019)

MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis
por: Csak, Timea, et al.
Publicado: (2015)

Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis
por: Sebastiani, Giada, et al.
Publicado: (2015)

Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model
por: Li, Hua, et al.
Publicado: (2019)

Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
por: Yokomori, Hiroaki, et al.
Publicado: (2020)

Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model
por: Hamada, Shintaro, et al.
Publicado: (2022)

Role of aramchol in steatohepatitis and fibrosis in mice
por: Iruarrizaga‐Lejarreta, Marta, et al.
Publicado: (2017)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease
por: Ayoub, Fares, et al.
Publicado: (2018)

Characterization of High-Fat, Diet-Induced, Non-alcoholic Steatohepatitis with Fibrosis in Rats
por: Xu, Zheng-Jie, et al.
Publicado: (2009)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis
por: Li, Yadi, et al.
Publicado: (2021)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj223atgkm39th6va8n3k4205a